Quebec Implements Public Reimbursement of Pluvicto® – A Defining Milestone for Radioligand Therapy in Canada
Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer Momentum builds nationwide as more jurisdictions recognize radioligand as… Read More